Drugs / Etavopivat C
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06609226 | Jan 2025 → Dec 2030 expected | sickle cell disease, thalassemia | Novo Nordisk A/S | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Etavopivat C | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06609226 ↗ |
| Route | Oral | “Participants will receive an oral dose of Etavopivat C.” NCT06609226 ↗ |